Personalizing Medicine through AI

Our Approach

Focused on Changing Breast Cancer Outcomes

PreciseDx® is dedicated to supporting more personalized and precise treatments for breast cancer.

 

On average, every two minutes a woman is diagnosed with breast cancer in the United States.

About 1 in 8 U.S. women (about 2.3 million diagnosed annually) will develop invasive breast cancer over the course of their lifetime.

About PreciseDx

PreciseDx® is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.

Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping, and image analysis
Providing unmatched insights to support pathologists, and oncologists

Better Data. Better Outcomes.

PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.

  • Patients
  • Providers
  • Payers
  • BioPharma

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

Patients

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

Providers

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

Payers

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

BioPharma

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

Gold Corporate Member
Jack Zeineh, PreciseDx
Gold Corporate Member

Featured News & Resources

Media Coverage
August 22, 2024
LabPulse
PreciseDx raises $20.7M in series B funding
Media Coverage
August 22, 2024
CityBiz
PreciseDx Raises $20.7M Series B
Media Coverage
August 22, 2024
Femtechworld
Start-up raises US$20.7m to ‘advance’ AI-based cancer risk assessments

Interested in Learning More?

Contact Us